Key result
Lovastatin reduces first acute major coronary events in patients with average LDL and low HDL.
Why the study?
Does lovastatin reduce the risk for the first acute major coronary event in men and women with average TC and LDL-C levels and below-average HDL-C levels?
Does lovastatin reduce the risk for the first acute major coronary event in men and women with average TC and LDL-C levels and below-average HDL-C levels?
Lovastatin reduces the risk of first acute major coronary events in patients with average LDL-C but below-average HDL-C, suggesting a need to reassess guidelines.
Answers are grounded in this paper and cite their sources.
Supports statin use for primary prevention in average-LDL low-HDL patients; extends evidence beyond hypercholesterolemia.
Lovastatin reduces the risk for the first acute major coronary event in men and women with average TC and LDL-C levels and below-average HDL-C levels. These findings support the inclusion of HDL-C in risk-factor assessment, confirm the benefit of LDL-C reduction to a target goal, and suggest the need for reassessment of the National Cholesterol Education Program guidelines regarding pharmacological intervention.
No takes yet. Share an insight, caveat, or question.
Downs et al. (1998) studied Primary prevention of acute coronary events in individuals with average total cholesterol and LDL-C levels and below-average HDL-C levels. Lovastatin was evaluated on First acute major coronary event. Lovastatin reduced the risk for the first acute major coronary event in men and women with average total and LDL cholesterol and below-average HDL cholesterol levels.
Synapse has enriched 10 related papers. Consider them for comparative context: